<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="752">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02370524</url>
  </required_header>
  <id_info>
    <org_study_id>[18F]T807</org_study_id>
    <nct_id>NCT02370524</nct_id>
  </id_info>
  <brief_title>Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease</brief_title>
  <official_title>Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molecular NeuroImaging</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute for Neurodegenerative Disorders</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Molecular NeuroImaging</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this exploratory imaging study is to further characterize [18F]T807,&#xD;
      an investigational PET radioligand for imaging Tau (thought to be a downstream biomarker&#xD;
      indicative of neurodegeneration in conditions such as AD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative evaluation of [18F]T807 as a potential PET radioligand for imaging Tau in patients with clinically characterized tauopathies</measure>
    <time_frame>1 year</time_frame>
    <description>To further characterize [18F]T807, an investigational PET radioligand for imaging Tau (thought to be a downstream biomarker indicative of neurodegeneration in conditions such as AD) and to assess the full quantitative evaluation of the PET outcome measures using [18F]T807 by pharmacokinetic (PK) modeling in order to derive a volume of distribution (VT) of [18F]T807 using arterial input function.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Alzheimer's Disease (AD)</condition>
  <arm_group>
    <arm_group_label>[18F]T807</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the [18F]T807 PET imaging visit, subjects will be given a bolus injection of no more than 10 mCi (370 MBq) of [18F]T807</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]T807</intervention_name>
    <description>All enrolled subjects will undergo an [18F]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.</description>
    <arm_group_label>[18F]T807</arm_group_label>
    <other_name>Amyvid</other_name>
    <other_name>[18F]florbetapir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For all Subjects:&#xD;
&#xD;
          -  Written informed consent or assent is obtained&#xD;
&#xD;
          -  Female subjects/volunteers must be either surgically sterile (by means of&#xD;
             hysterectomy, bilateral oophorectomy, or tubal ligation) or post-menopausal for at&#xD;
             least 1 year or, if they are of childbearing potential, must commit to the use of two&#xD;
             effective contraception methods for the duration of the study.&#xD;
&#xD;
          -  Male subjects/volunteers and their partners of childbearing potential must commit to&#xD;
             the use of two effective methods of contraception, one of which should be a barrier&#xD;
             method for male subjects.&#xD;
&#xD;
        Prodromal and Mild Alzheimer's Disease Subjects&#xD;
&#xD;
          -  Males and females aged between 50 and 90 years.&#xD;
&#xD;
          -  Study partner has noticed a recent gradual decrease in the subject's memory (e.g.,&#xD;
             over the prior 12 months), which the subject may or may not be aware of.&#xD;
&#xD;
          -  For prodromal subjects, abnormal memory function at screening or 4 weeks prior to&#xD;
             screening based on the FCSRT-IR of:Free recall &lt;17, or Total recall &lt;40, or Free&#xD;
             recall &lt;20 and total recall &lt;42.&#xD;
&#xD;
          -  Individuals with mild AD must meet the criteria based on the National Institute of&#xD;
             Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related&#xD;
             Disorders Association and Diagnostic and Statistical Manual of Mental Disorders,&#xD;
             Version 5, criteria. This evidence may be compiled during screening but must be fully&#xD;
             documented in the subject's study file before the baseline visit.&#xD;
&#xD;
          -  Have an MMSE (Folstein et al. 1975) score at screening &gt;20.&#xD;
&#xD;
          -  Have an Amyvid (florbetapir F 18 injection) scan at screening that demonstrates&#xD;
             amyloid binding based on qualitative analysis (visual read) that meets the criteria&#xD;
             for AD.&#xD;
&#xD;
          -  Modified Hachinski Ischemia Scale (Moroney et al. 1997) score of ≤ 4.&#xD;
&#xD;
          -  A neuroimaging evaluation of the brain by MRI that supports a diagnosis of AD with no&#xD;
             evidence of focal disease to account for dementia or MRI exclusion criteria.&#xD;
&#xD;
          -  Medications taken for symptomatic treatment of AD must be maintained on a stable&#xD;
             dosage regimen for at least 4 weeks before the [18F]T807 imaging visit.&#xD;
&#xD;
          -  Able to participate in all scheduled evaluations.&#xD;
&#xD;
          -  The subject has an appropriate caregiver or community dwelling with a caregiver&#xD;
             capable of accompanying the subject on all visits to the center as judged by the&#xD;
             investigator.&#xD;
&#xD;
          -  In the opinion of the investigator, the subject and caregiver will be compliant and&#xD;
             have a high probability of completing the study.&#xD;
&#xD;
        Healthy Volunteers&#xD;
&#xD;
          -  Males and females aged between 20 and 90 years. Younger healthy controls will be aged&#xD;
             20-49 and older healthy controls will be aged 50-90.&#xD;
&#xD;
          -  Healthy volunteers with no clinically relevant findings on physical examination at&#xD;
             screening and upon reporting for the [18F]T807 imaging visit.&#xD;
&#xD;
          -  No suspicion of cognitive impairment/early dementia from MMSE as judged by the&#xD;
             investigator (MMSE&gt;28).&#xD;
&#xD;
          -  No concomitant medications, over-the-counter, supplement, or any other agent intended&#xD;
             to improve cognition or prevent cognitive decline&#xD;
&#xD;
          -  A negative Amyvid (florbetapir F 18 injection) scan at screening based on qualitative&#xD;
             analysis (visual read).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For All subjects:&#xD;
&#xD;
          -  Current or prior history of any alcohol or drug abuse.&#xD;
&#xD;
          -  Severe systemic disease based on history and physical examination.&#xD;
&#xD;
          -  Positive result on urine screen for illicit drugs.&#xD;
&#xD;
          -  Laboratory tests with clinically significant abnormalities&#xD;
&#xD;
          -  Clinically significant unstable medical or psychiatric illness.&#xD;
&#xD;
          -  Positive test for hepatitis B or C or HIV.&#xD;
&#xD;
          -  Prior participation in other research protocols or clinical care in the last year such&#xD;
             that radiation exposure is &gt;15 mSv and participation in this study would require the&#xD;
             subject/volunteer to exceed the annual limits.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Current or prior history of coagulopathy.&#xD;
&#xD;
          -  The subject has evidence of clinically significant gastrointestinal, cardiovascular,&#xD;
             hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency,&#xD;
             pulmonary, or other disorder or disease.&#xD;
&#xD;
          -  History of significant drug and/or food allergies, anaphylactic/anaphylactoid reaction&#xD;
             to any allergen.&#xD;
&#xD;
          -  Contraindication for arterial cannulation.&#xD;
&#xD;
          -  Unsuitable veins for repeated venipuncture.&#xD;
&#xD;
          -  MRI exclusion criteria include: non-AD pathology such as infectious disease,&#xD;
             space-occupying lesions, normal pressure hydrocephalus, or any other abnormalities&#xD;
             associated with significant CNS disease&#xD;
&#xD;
          -  Any lacunar infarct in a strategically important location known to lead to cognitive&#xD;
             impairment such as the thalamus, hippocampus of either hemisphere, or head of the left&#xD;
             caudate&#xD;
&#xD;
          -  Severe sub-cortical microvascular disease (Fazekas score of 3 for deep white matter&#xD;
             hyperintensities) (Fazekas et al. 1987)&#xD;
&#xD;
          -  Territorial infarct or macroscopic hemorrhage (&gt;10 mm)&#xD;
&#xD;
          -  Implants such as implanted cardiac pacemakers or defibrillators, insulin pumps,&#xD;
             cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS&#xD;
             aneurysm clips or other medical implants that have not been certified for MRI, or&#xD;
             history of claustrophobia in MRI&#xD;
&#xD;
          -  Observed claustrophobia at screening&#xD;
&#xD;
          -  Ferromagnetic foreign bodies, such as metal shrapnel or bullet fragments, need to be&#xD;
             considered on an individual basis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danna Jennings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Neurodegenerative Disorders</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Molecular NeuroImaging, LLC</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.indd.org</url>
    <description>Institute for Neurodenerative Disorders</description>
  </link>
  <reference>
    <citation>Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987 Aug;149(2):351-6.</citation>
    <PMID>3496763</PMID>
  </reference>
  <reference>
    <citation>Folstein MF, Folstein SE, McHugh PR. &quot;Mini-mental state&quot;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98.</citation>
    <PMID>1202204</PMID>
  </reference>
  <reference>
    <citation>Moroney JT, Bagiella E, Desmond DW, Hachinski VC, Mölsä PK, Gustafson L, Brun A, Fischer P, Erkinjuntti T, Rosen W, Paik MC, Tatemichi TK. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology. 1997 Oct;49(4):1096-105.</citation>
    <PMID>9339696</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2015</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Molecular NeuroImaging</investigator_affiliation>
    <investigator_full_name>Danna Jennings</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

